The India launch of Eli Lilly’s popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive pressure ...

The acquisition – which is due to close before year-end – marks another departure from Novo Nordisk's traditional focus of diabetes and obesity, which has also seen it move into areas like ...